Dysregulation in the Expression of Platelet Surface Receptors in Acute Coronary Syndrome Patients-Emphasis on P2Y12

被引:2
|
作者
Szelenberger, Rafal [1 ,2 ]
Karbownik, Michal Seweryn [3 ]
Kacprzak, Michal [4 ]
Synowiec, Ewelina [5 ]
Michlewska, Sylwia [6 ]
Bijak, Michal [2 ]
Zielinska, Marzenna [4 ]
Olender, Alina [7 ]
Saluk-Bijak, Joanna [1 ]
机构
[1] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biochem, PL-90236 Lodz, Poland
[2] Univ Lodz, Fac Biol & Environm Protect, Biohazard Prevent Ctr, PL-90236 Lodz, Poland
[3] Med Univ Lodz, Dept Pharmacol & Toxicol, PL-90752 Lodz, Poland
[4] Med Univ Lodz, Dept Intervent Cardiol, PL-91213 Lodz, Poland
[5] Univ Lodz, Fac Biol & Environm Protect, Med Genet Lab, PL-90236 Lodz, Poland
[6] Univ Lodz, Fac Biol & Environm Protect, Lab Microscop Imaging & Specialized Biol Tech, PL-90237 Lodz, Poland
[7] Med Univ Lublin, Chair & Dept Med Microbiol, PL-20093 Lublin, Poland
来源
BIOLOGY-BASEL | 2022年 / 11卷 / 05期
关键词
blood platelets; acute coronary syndrome; surface receptors; miRNA; GP IIb; IIIa; MICRORNA; PROTEIN; ACTIVATION; DYNAMICS; MIR-223;
D O I
10.3390/biology11050644
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Simple Summary Acute Coronary Syndrome is a disease of the circulatory system characterized by the partial or complete blockage of coronary arteries. In thrombosis, a major role is played by platelets-the smallest, anucleate, morphotic elements in the bloodstream. Platelets are involved in the process of hemostasis, which ensures the continuity of the blood vessel by forming a clot that prevents blood loss. Unique structures of blood platelets ensure their high reactivity in the vascular microenvironment due to the interaction with many biologically active molecules, which is recognized by the surface receptors. The research carried out in the manuscript is aimed at detecting potential changes at the molecular level in platelet surface receptors that could constitute the potential importance of the occurrence of Acute Coronary Syndrome. The obtained results indicate that the P2Y12 receptor, which is the main target of antiplatelet therapy, is expressed more frequently among patients. In addition, we have shown that at the genetic level, quantitative changes also occur in the case of other receptors that are important in the activation of platelets. The following manuscript suggests the potential mechanisms responsible for the differences between patients and healthy donors due to a better understanding of the molecular causes of Acute Coronary Syndrome pathogenesis. The pathological conditions caused by blood platelet activation constitute a fundamental core in the pathogenesis of Acute Coronary Syndrome (ACS). The hyperactivity of platelets in ACS is well-documented, but there is still little research into the molecular basis of phenotypic changes in platelet functionality. To expand the knowledge of this phenomenon, we analyzed the disturbances in the expression of several key platelet receptors and the aspect of regulating potential abnormalities. Platelet surface receptors are responsible for maintaining the hemostatic balance, platelet interaction with immune cells, and support of the coagulation cascade leading to occlusion of the vessel lumen. Due to their prominent role, platelet receptors constitute a major target in pharmacological treatment. Our work aimed to identify the molecular alteration of platelet surface receptors, which showed augmented mRNA expression of P2Y12, GP1BB, ITGA2B, and ITGB3 and increased protein concentrations of P2Y12 and GP IIb/IIIa in ACS. The upregulation of the P2Y12 level was also confirmed by confocal and cytometric visualization. Furthermore, we evaluated the expression of two microRNAs: miR-223-3p and miR-126-3p, which were suggested to regulate platelet P2Y12 expression. Results of our study present new insight into the molecular background of ACS.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Efficacy and safety of newer P2Y12 inhibitors versus clopidogrel in patients with acute coronary syndrome
    Fei, Y.
    Lam, C.
    Cheung, B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1631 - 1631
  • [22] Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina
    Taylor C. Bazemore
    Michael G. Nanna
    Sunil V. Rao
    Journal of Thrombosis and Thrombolysis, 2017, 44 : 303 - 315
  • [23] Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
    Song, Kai
    Jin, Xuan
    Kim, Moo-Hyun
    Li, Jia-Xin
    Jin, Cai-De
    Yuan, Song-Lin
    Song, Zhao-Yan
    Jin, En-Ze
    Lee, Kwang-Min
    Lim, Kyung-Hee
    Cho, Young-Rak
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [24] Reversible P2Y12 inhibitor versus irreversible P2Y12 inhibitor in ACS patients undergoing PCI (the acute coronary syndrome israeli survey (ACSIS)
    Eliaz, R.
    Mengesha, B.
    Ovdat, T.
    Iakobishvili, Z.
    Hasdai, D.
    Kheifets, M.
    Klempfner, R.
    Beigel, R.
    Kalmanovich, E.
    Alcalai, R.
    Levi, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1414 - 1414
  • [25] Patterns of use of P2Y12 inhibitors in patients with acute coronary syndrome in routine clinical practice
    Yuan, Zhong
    Hardin, Jill
    Voss, Erica A.
    Hester, Laura L.
    Weaver, James
    Davis, Kourtney
    Barnathan, Elliot S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 143 - 143
  • [26] Exploring The Risks And Benefits of Upstream Loading of P2Y12 inhibitors In Acute Coronary Syndrome Patients
    Lim, William
    Htwe, Khaing Khaing
    Ahmad, Muhammad
    Khan, Ali Akram
    Changezi, Hameem
    CIRCULATION, 2024, 150
  • [27] Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome
    Grosdidier, Charlotte
    Blanz, Kelly D.
    Deharo, Pierre
    Bernot, Denis
    Poggi, Marjorie
    Bastelica, Delphine
    Wolf, Dennis
    Duerschmied, Daniel
    Grino, Michel
    Cuisset, Thomas
    Alessi, Marie-Christine
    Canault, Matthias
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (04) : 684 - 694
  • [28] Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes
    Moon, Jungyeon
    Ozaki, Aya F.
    Chong, Alice
    Sud, Maneesh
    Fang, Jiming
    Austin, Peter C.
    Ko, Dennis T.
    Jackevicius, Cynthia A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [29] P2Y12 antagonists in acute coronary syndrome: In whom should they be started, and when?
    Good C.W.
    Berger P.B.
    Current Cardiology Reports, 2011, 13 (4) : 320 - 326
  • [30] A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs
    Wei Eric Wang
    Hongyong Wang
    Xukai Wang
    Chunyu Zeng
    Journal of Thrombosis and Thrombolysis, 2014, 37 : 102 - 106